Evofem Biosciences, Inc. (EVFM)
0.0067
0.00 (0.00%)
USD |
OTCM |
Oct 23, 16:00
Evofem Biosciences Gross Profit Margin (Quarterly) : 80.06% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 80.06% |
| March 31, 2026 | 46.05% |
| December 31, 2025 | 71.91% |
| September 30, 2025 | 80.11% |
| June 30, 2025 | 82.13% |
| March 31, 2025 | 30.41% |
| December 31, 2024 | 74.17% |
| September 30, 2024 | 73.84% |
| June 30, 2024 | 80.50% |
| March 31, 2024 | 79.38% |
| December 31, 2023 | 78.90% |
| September 30, 2023 | 61.33% |
| Date | Value |
|---|---|
| June 30, 2023 | -28.97% |
| March 31, 2023 | 63.42% |
| December 31, 2022 | -801.1% |
| September 30, 2022 | 69.71% |
| June 30, 2022 | 76.12% |
| March 31, 2022 | 59.40% |
| December 31, 2021 | 32.52% |
| September 30, 2021 | 7.59% |
| June 30, 2021 | 21.38% |
| March 31, 2021 | 6.70% |
| December 31, 2020 | -262.5% |
| September 30, 2020 | -98.92% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |
| Veru, Inc. | -- |
| Johnson & Johnson | 68.11% |
| Eli Lilly & Co. | 85.78% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -120.5% |
| Profit Margin (Quarterly) | -419.1% |
| Operating Margin (Quarterly) | -94.53% |
| Return on Net Operating Assets | -138.7% |